{"id":"tislelizumab-sox-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of Tislelizumab and SOX chemotherapy is thought to work synergistically to enhance the body's immune response against cancer cells while also inducing DNA damage and apoptosis in rapidly dividing cancer cells. This dual mechanism of action may lead to improved efficacy in treating certain types of cancer.","oneSentence":"Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, thereby enhancing the body's immune response against cancer cells. SOX chemotherapy is a combination of platinum-based and anthracycline-based chemotherapeutic agents that work by inducing DNA damage and apoptosis in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:55.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT06826079","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-01","conditions":"Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy","enrollment":80},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT07068516","phase":"PHASE3","title":"Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xiangdong Cheng","startDate":"2025-07-20","conditions":"Gastric Cancer Stage","enrollment":470},{"nctId":"NCT06939439","phase":"PHASE3","title":"Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":"Gastric Cancer Stage III","enrollment":416},{"nctId":"NCT06685887","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-15","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06760858","phase":"","title":"A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":122},{"nctId":"NCT06682182","phase":"","title":"Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer with Peritoneal Metastasis","enrollment":74},{"nctId":"NCT06451211","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-17","conditions":"Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach","enrollment":53},{"nctId":"NCT06374901","phase":"PHASE2","title":"Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Xiangdong Cheng","startDate":"2024-04-25","conditions":"Gastric Cancer","enrollment":134},{"nctId":"NCT06238167","phase":"PHASE2","title":"Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-04-01","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06118658","phase":"PHASE2","title":"Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2023-11-01","conditions":"Gastric, Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT05687357","phase":"PHASE2","title":"Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-03-15","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab + SOX Chemotherapy","genericName":"Tislelizumab + SOX Chemotherapy","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, thereby enhancing the body's immune response against cancer cells. SOX chemotherapy is a combination of platinum-based and anthracycline-based chemotherapeutic agents that work by inducing DNA damage and apoptosis in rapidly dividing cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}